• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Circulating endothelial progenitor cells in multiple myeloma: implications and significance

      Thumbnail
      View / Download
      520.5 Kb
      Author(s)
      Zhang, H.
      Vakil, V.
      Braunstein, M.
      Smith, E. L. P.
      Maroney, J.
      Chen, L.
      Dai, K.
      Berenson, J. R.
      Hussain, M. M.
      Klueppelberg, U.
      Norin, A. J.
      Akman, H. O.
      Özçelik, T.
      Batuman, O. A.
      Date
      2005
      Source Title
      Blood
      Print ISSN
      0006-4971
      Electronic ISSN
      1528-0020
      Publisher
      American Society of Hematology
      Volume
      105
      Issue
      8
      Pages
      3286 - 3294
      Language
      English
      Type
      Article
      Item Usage Stats
      137
      views
      139
      downloads
      Abstract
      Angiogenesis governs the progression of multiple myeloma (MM). Circulating endothelial cells (CECs) contribute to angiogenesis and comprise mature ECs and endothelial progenitor cells (EPCs). The present study sought to characterize CECs and their relation to disease activity and therapeutic response in 31 consecutive patients with MM. CECs, identified as CD34+/CD146+/CD105+/CD11b- cells, were 6-fold higher in patients compared to controls and correlated positively with serum M protein and β2-microglobulin. Circulating EPCs displayed late colony formation/outgrowth and capillary-like network formation on matrigel; these processes were inhibited after effective thalidomide treatment. Co-expression of vascular endothelial growth factor receptor-2 (KDR) and CD133 characterized EPCs in MM, and KDR mRNA elevations correlated with M protein levels. In vitro exposure of ECs to thalidomide or its derivative CC-5013 inhibited gene expression of the receptors for transforming growth factor-β and thrombin. Thus, elevated levels of CECs and EPCs covary with disease activity and response to thalidomide, underscoring the angiogenic aspect of MM and suggesting that angioblastlike EPCs are a pathogenic biomarker and a rational treatment target in MM. The results also highlight the anti-angiogenic properties of thalidomide and CC-5013 and further elucidate possible mechanisms of their effectiveness against MM.
      Permalink
      http://hdl.handle.net/11693/48717
      Published Version (Please cite this version)
      https://doi.org/10.1182/blood-2004-06-2101
      Collections
      • Department of Molecular Biology and Genetics 468
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartments

      My Account

      LoginRegister

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 1771
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy